NNVC NanoViricides Inc
Company Analysis
Latest News
🟢 NanoViricides is trading 13.67% up in pre-market
NanoViricides is trading 13.67% higher at $1.58 in pre-market on October 23, compared with the October 22 close of $1.39. No new company-specific announcement...
🔴 NanoViricides is trading 5% down amid broader risk-off sentiment
NanoViricides is trading 5.28% down now at $1.43 on October 22, 2026, with no confirmed company-specific catalyst identified. - A recent prospectus filing for...
🔴 NanoViricides is trading 5% down in after-hours trading; no confirmed catalyst identified
NanoViricides is trading at $1.43, down 5.30%, after its October 21 regular-session close at $1.51; no catalyst is confirmed. - An October 21 report noted a...
🟢 NanoViricides is trading 5% up in pre-market with no clear company-specific catalyst identified
NanoViricides is trading at $1.56, up 5.39% in the October 21 pre-market, with no clear overnight company-specific catalyst identified. - On October 20,...
🔴 NanoViricides is trading 14.86% down in pre-market — no clear overnight catalyst
NanoViricides is trading 14.86% lower at $1.26 before the October 21, 2026 open, with no clear overnight company-specific catalyst identified. - It closed at...
🟢 NanoViricides is trading 12% up today after positive NV-387 juvenile-mouse safety results
NanoViricides is trading 12.31% higher at $1.46 after announcing positive juvenile-mouse safety results for NV-387 on October 20, 2026. - The candidate was...
NanoViricides Shares Jump 8% on Positive Mouse Study, but Can Preclinical Data Justify a Path to Real Revenue?
Shares of NanoViricides (NNVC) surged 8.5% to $1.41 on October 20 after the clinical-stage biotech announced that its antiviral drug candidate, NV-387, showed...
🟢 NanoViricides is trading 8.5% up on October 20, 2026, after NV-387 showed favorable juvenile safety results
NanoViricides is trading at $1.41, up 8.46%, alongside its October 20, 2026 announcement that NV-387 showed favorable safety and tolerability in a juvenile...
🔴 NanoViricides is trading 5% down with no clear catalyst
NanoViricides is trading at $1.31, down 5.07%, with no company-specific explanation for the October 19 decline in available reporting. - Its latest listed...
🟢 NanoViricides rises 6.1% — Biotech Sector Rallies on Positive Clinical Data and Regulatory News
With Biotech (XBI) up 2.2%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector, as measured by the XBI ETF,...
🟢 NanoViricides is trading 6% up in pre-market; Ebola trial update's role is unconfirmed
NanoViricides is trading at $1.40, up 5.95% in pre-market, with its Ebola trial update as relevant but unconfirmed context. - On October 13, 2026,...
🟢 NanoViricides is trading 5.3% up in after-hours trading alongside Ebola trial enrollment update
NanoViricides is trading at $1.40, up 5.26% in after-hours trading; its Ebola trial update is possible context, not a confirmed cause. - On October 13, 2026,...
🟢 NanoViricides rises 5.3% — Biotech Sector Rallies on Strong IPO Debuts and M&A Activity
With Biotech (XBI) up 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector is experiencing a significant rally,...
🔴 NanoViricides is trading 5.6% down; cause remains unclear
NanoViricides is trading 5.6% lower at $1.36 on October 8, 2026, with no clear company-specific catalyst identified. - Shares pulled back from the October 7...
🟢 NanoViricides is trading 5% up today with no clear catalyst identified
NanoViricides is trading 5.00% higher at $1.47 on October 7, 2026, with no clear company-specific catalyst identified. - The company announced a presentation...
🔴 NanoViricides is trading 5.2% down on October 6, 2026 with XBI down 2.50%
NanoViricides is trading at $1.37, a change of -5.19%, with biotech-sector pressure the clearest available context. - XBI fell 2.50% in the session, while...
NanoViricides Jumps 10% on Ebola Trial Update, but Can a Phase IIA Study Justify the Hype?
Shares of NanoViricides (NNVC) surged 10.5% to $1.42 on October 5 after the company confirmed its NV-387 Phase IIA clinical trial for Ebola is proceeding as...
🟢 NanoViricides is trading 11% up today amid an NV-387 Ebola trial update
NanoViricides is trading at $1.42, up 10.55%, alongside an update that its NV-387 Phase II Ebola trial is proceeding as designed. - On October 5, 2026, the...
🟢 NanoViricides soars 7.1% on positive NV-387 Ebola trial update
NanoViricides surged 7.1% to $1.37 today after providing a positive update on its NV-387 Phase IIA Ebola trial. - The company announced on October 5, 2026,...
🟢 NanoViricides is trading 7% up amid Ebola trial update
NanoViricides is trading 7.03% higher at $1.37, with its October 5 Phase II Ebola trial update a possible catalyst; a direct link to the move is unconfirmed. -...